Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.42 CNY
−513.88 M CNY
418.73 M CNY
581.97 M
About HYBIO PHARMACEUTIC
Sector
CEO
Yu Pin Xiang
Headquarters
Shenzhen
Website
Founded
2003
ISIN
CNE1000011T7
FIGI
BBG001F74L77
Hybio Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sales of chemically synthesized peptide drugs. Its products include atosiban, carbetocin, desmopressin, eptifibatide, ganirelix, glatiramer, terlipressin, octreotide, liraglutide, and trimetazidine tablets. The company was founded on April 2, 2003 and is headquartered in Shenzhen, China.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 300199 is 14.12 CNY — it has increased by 2.69% in the past 24 hours. Watch HYBIO PHARMACEUTIC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on SZSE exchange HYBIO PHARMACEUTIC stocks are traded under the ticker 300199.
300199 stock has risen by 13.36% compared to the previous week, the month change is a 21.58% rise, over the last year HYBIO PHARMACEUTIC has showed a 5.45% increase.
300199 reached its all-time high on Jun 10, 2015 with the price of 52.76 CNY, and its all-time low was 2.79 CNY and was reached on Dec 4, 2012. View more price dynamics on 300199 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
300199 stock is 12.50% volatile and has beta coefficient of 1.62. Track HYBIO PHARMACEUTIC stock price on the chart and check out the list of the most volatile stocks — is HYBIO PHARMACEUTIC there?
Today HYBIO PHARMACEUTIC has the market capitalization of 12.54 B, it has decreased by −0.45% over the last week.
Yes, you can track HYBIO PHARMACEUTIC financials in yearly and quarterly reports right on TradingView.
HYBIO PHARMACEUTIC is going to release the next earnings report on Apr 24, 2025. Keep track of upcoming events with our Earnings Calendar.
300199 net income for the last quarter is −24.45 M CNY, while the quarter before that showed 3.74 M CNY of net income which accounts for −753.10% change. Track more HYBIO PHARMACEUTIC financial stats to get the full picture.
As of Dec 25, 2024, the company has 895.00 employees. See our rating of the largest employees — is HYBIO PHARMACEUTIC on this list?
Like other stocks, 300199 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HYBIO PHARMACEUTIC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So HYBIO PHARMACEUTIC technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating HYBIO PHARMACEUTIC stock shows the buy signal. See more of HYBIO PHARMACEUTIC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.